An experimental drug shows promise as an effective new approach for treating multiple sclerosis and the intestinal ailment Crohn's disease. In preliminary tests, the new drug Antegren dramatically ...
B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...
Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when started earlier.
Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...
Early intervention and effective therapies are transforming multiple sclerosis management, enhancing patient outcomes, and delaying disability progression. In recent years, the management of multiple ...
A generation ago, most people with multiple sclerosis could expect to rely on walkers and wheelchairs or be limited to their bed within 15 years of diagnosis. Today, UC San Francisco’s discoveries are ...
Doctors have traditionally used a "step-up," also known as the "escalation," approach for treating multiple sclerosis (MS), the neurodegenerative disease that affects the central nervous system. Using ...
Zeposia (ozanimod) is a prescription drug used to treat certain forms of multiple sclerosis (MS) in adults. Zeposia is a brand-name drug and is not currently available in a generic version. Zeposia ...
7d
Art Alexakis Frontman Opens Up About His Workouts, Diet, and Treatment to Manage Multiple Sclerosis
An estimated 2.8 million people worldwide are living with multiple sclerosis (MS), according to the National MS Society.
Hosted on MSN
How multiple sclerosis is treated
Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune response. Copaxone and Glatopa mimic a protein in myelin to ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
Expert Rev Neurother. 2008;8(3):433-455. Three formulations of DAC have been tested in humans so far: intravenously administered Zenapax ® (marketed by Roche) was tested and is approved for treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results